• News
  • SAN DIEGO
  • BioTech

Neurocrine nets $9.5 million in 4Q

Neurocrine Biosciences Inc. (Nasdaq: NBIX) Friday announced its net income for the fourth quarter of 2012 rose to $9.5 million or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
24.49
  0.59  
+ 2.47%
2,187,103,000
24.86
8.99

Insider Trade Data

Date Insider Shares Type Value
12/19/2014 Coughlin, Timothy P 30,000 Sell $703,800
12/19/2014 Coughlin, Timothy P 30,000 Exchange $77,700
12/19/2014 Gorman, Kevin Charles 70,000 Sell $1,638,350
12/19/2014 Gorman, Kevin Charles 70,000 Exchange $295,150
12/19/2014 O Brien, Christopher F 20,000 Sell $480,400

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
Subscribe Today!